Founded in 2006 by Prof. Nicholas S. Bodor to further the development and therapeutic potential of his novel Retrometabolic Drug Design and Targeting concepts. Traditionally, development of therapeutics targeted to exploit newly identified pathways results in exceptionally high rates of drug failures, either through lack of effectiveness or unacceptable toxicity. The Retrometabolic Drug Design process provides a means of capit...
Founded in 2006 by Prof. Nicholas S. Bodor to further the development and therapeutic potential of his novel Retrometabolic Drug Design and Targeting concepts. Traditionally, development of therapeutics targeted to exploit newly identified pathways results in exceptionally high rates of drug failures, either through lack of effectiveness or unacceptable toxicity. The Retrometabolic Drug Design process provides a means of capitalizing on known pathways and therapeutics to develop novel compounds that have considerably less side-effects and clear paths to approval success.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.